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Abstract
Pathological changes in iron status are known to occur during bypass and will be superimposed upon physiological
abnormalities in iron distribution, characteristic of the neonatal period. We have sought to define the severity of iron
overload in these patients. Plasma samples from 65 paediatric patients undergoing cardiopulmonary bypass (CPB) were
analysed for non-haem iron, total iron binding capacity, transferrin and bleomycin-detectable iron. Patients were divided
into four age groups for analysis. Within each age group, patients who were in iron overload at any time point were
statistically compared to those who were not. The most significant changes in iron chemistry were seen in the plasma of
neonates, with 25% in a state of plasma iron overload. 18.5% of infants and 14.3% of children at 1^5 years were also in iron
overload at some time point during CPB. No children over 5 years, however, went into iron overload. Increased iron
saturation of transferrin eliminates its ability to bind reactive forms of iron and to act as an antioxidant. When transferrin is
fully saturated with iron, reactive forms of iron are present in the plasma which can stimulate iron-driven oxidative reactions.
Our data suggest that paediatric patients are at greater risk of iron overload during CPB, and that some form of iron
chelation therapy may be advantageous to decrease oxidative stress. ß 2000 Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Iron is a transition metal widely used in nature to
transfer electrons, transport oxygen and act catalyti-
cally at the active centre of oxidases, oxygenases and
certain antioxidants (reviewed in [1]). The ability of
iron to redox cycle and transfer electrons to molec-
ular oxygen to form a variety of reactive oxygen
species (ROS) has necessitated the evolution of li-
gands that decrease or prevent unwanted electron
transfers. Thus, iron transporting proteins such as
transferrin and lactoferrin, and iron storage proteins
such as ferritin and haemosiderin, sequester iron in
forms that minimise the transfer of electrons from
iron to molecular oxygen [2,3].
Most cells contain a pool of low molecular mass
iron (LMrFe) for the synthesis of iron-containing
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proteins and DNA, whereas most extracellular £uids
normally do not. Normal human plasma, therefore,
contains no detectable LMrFe because the iron bind-
ing protein transferrin is only around 30% loaded
with iron retaining a considerable iron binding ca-
pacity. When, however, the release of chelatable iron
exceeds the iron binding capacity of transferrin,
LMrFe can be detected and measured in plasma,
using techniques such as the bleomycin assay [4].
Plasma iron overload can be found in a variety of
pathological conditions (reviewed in [5]) as well as
physiologically in the neonate [6,7]. A high percent-
age of blood samples from term and pre-term neo-
nates show full iron saturation of transferrin with the
presence of LMrFe in the plasma [6,7] and some of
this iron may be present in the highly reactive ferrous
(Fe2) form [8]. Ferrous salts have the potential to
transfer electrons directly to molecular oxygen to
form ROS. Neonates have antioxidant defences pro-
foundly di¡erent from adults and these do not ap-
pear to cope well with the additional generation of
ROS [9,10]. When pro-oxidants, such as LMrFe, are
increased or antioxidant protection diminished a sit-
uation of oxidative stress will ensue.
During adult cardiopulmonary bypass iron is re-
leased as a result of the extracorporeal circulation of
blood [11], ischaemia^reperfusion [12] and blood car-
dioplegias [13]. A combination of these factors in-
creases the iron saturation of transferrin in all adult
bypass patients to over 50%. Of these some 19% will
be in plasma iron overload with a fully iron-satu-
rated transferrin [11,13]. These ¢ndings in adults
prompted us to undertake a detailed study in neo-
nates, infants and children undergoing cardiopulmo-
nary bypass in whom pathological changes in iron
chemistry due to bypass will be superimposed upon
their physiological di¡erences in iron metabolism.
2. Materials and methods
Bleomycin sulphate and calf thymus DNA were
from the Sigma Chemical Co., Poole, Dorset, UK.
Radial immunodi¡usion plates for transferrin assays
were obtained from Dade Behring Diagnostics, Mil-
ton Keynes, UK. All other chemicals were of the
highest grades available from Fisher Scienti¢c UK,
Loughborough, Leics, UK.
2.1. Bypass blood samples
The study was approved by the Royal Brompton
Clinical Research Ethics Committee, and parents of
all subjects provided informed consent. Blood sam-
ples were collected into lithium heparin tubes and
sent to the laboratory for immediate separation.
Plasma was stored at 320‡C until the time of anal-
ysis, which was no longer than 7 days after separa-
tion.
2.2. Bypass conditions
Cross clamp, bypass and arrest times are summa-
rised in Table 1, together with mortality rates and
the type of cardioplegia used. The following age
groupings were made: Neonates, up to 1 month;
Infants, s 1 month to 1 year; Children s 1 year
to 5 years and Children s 5 years to 10 years.
Table 1
Summary of clinical cardiopulmonary bypass surgery details
Neonate Infants Children 1^5 years Children 5^10 years
N = 12 26 21 6
Sex (male) 7 11 10 2
Cross clamp time (min) 92.3 þ 7.7 (n = 11) 52.3 þ 4.1 (n = 25) 53.2 þ 6.9 (n = 19) 31.5 þ 5.4 (n = 6)
Bypass time (min) 132.7 þ 11.2 (n = 11) 83.7 þ 7.7 (n = 25) 74.2 þ 8.8 (n = 19) 45.3 þ 7.8 (n = 6)
Arrest time (min) 23.2 þ 4.5 (n = 11) 35.8 þ 9.1 (n = 6) 0 0
Mortality (n = ) 2 5 0 0
Cardioplegia
Blood (n = ) 3 12 8 2
Crystalloid (n = ) 9 14 13 4
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2.3. Bleomycin assay for LMrFe
Iron in plasma that is chelatable and redox active
was measured using the bleomycin assay [4]. Brie£y,
the reaction mixture contained DNA (1 mg/ml),
bleomycin (1.5 U/ml), Tris bu¡er (1 M pH 7.4), mag-
nesium chloride (50 mM) and the plasma sample (20
Wl). Ascorbic acid (7.5 mM) was added to start the
reaction and the mixture was incubated at 37‡C for
30 min. Any iron chelated from the plasma sample
by bleomycin was reduced to the ferrous state by
ascorbate. A ternary complex between iron, bleomy-
cin and DNA in the presence of molecular oxygen
formed oxo-iron species that degraded DNA and
released malondialdehyde (MDA) from the deoxyri-
bose sugar. MDA was measured spectrophotometri-
cally (A532 nm) after reacting it with 2-thiobarbituric
acid (TBA). To control for any TBA reactivity in the
plasma samples not produced by the bleomycin^
iron^DNA complex, a control was set up for each
sample. All the same reagents were used in the sam-
ple control except chelex-treated water was substi-
tuted for bleomycin. The result of this reaction was
then subtracted from the result obtained with bleo-
mycin.
Adventitious iron in reagents was removed as pre-
viously described [4]. LMrFe was quantitated with
reference to pure iron standards.
2.4. Total plasma non-haem iron and iron binding
capacity
The total plasma non-haem iron and the iron
binding capacity were measured using a Sigma kit
assay based on the ferrozine spectrophotometric
method.
2.5. Transferrin
Plasma transferrin was quantitated using radial
immunodi¡usion plates containing a polyclonal anti-
body to human transferrin and pure standards of
human apotransferrin. The percentage saturation of
transferrin with iron was derived from the measured
iron binding capacity. This was found to be in close
agreement with values calculated from the amount of
transferrin present. Where appropriate, values are
corrected to the plasma total protein value (assayed
by the Lowry technique) to adjust for haemodilution
inherent in bypass procedures.
2.6. Statistical analysis
Statistical comparisons were made using the
Mann^Whitney U-test.
3. Results
3.1. Low molecular mass iron
Neonates, as a group, showed more severe abnor-
malities in their iron chemistry before and during
cardiopulmonary bypass. One of the neonates (8%
of the total) was in iron overload before bypass,
and this iron overload was seen in all subsequent
samples during and after bypass, although the values
fell, presumably due to haemodilution (Table 2).
Two other neonates became iron-overloaded by the
end of bypass, representing 25% of the total in this
group. Neonates that showed iron overload at any
time point before, during or after bypass have been
grouped as the ‘bleomycin iron-positive’ sub-group
and statistically compared with those who did not
show BLM-Fe at any time point (Table 2).
3.2. Transferrin
Levels of plasma transferrin pre-bypass in the neo-
nates and infants were low when compared to nor-
mal healthy adult levels, but were within the normal
range expected for normal neonates and infants. As
bypass progressed, transferrin levels initially fell due
to haemodilution but then slowly recovered to reach
values somewhat lower than the pre-bypass levels
(Table 2).
3.3. Non-haem iron and iron overload
The amount of non-haem iron in the plasma in-
creased in all patient groups during bypass, although
the neonates showed higher pre-bypass levels. Values
appeared to fall initially, but increased towards the
end of bypass (Table 2). An increased release of iron
into the plasma accompanied by a falling level of
transferrin resulted in the transferrin becoming
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more loaded with iron, and decreasing the iron bind-
ing capacity of transferrin. The percentage saturation
of transferrin rose in all patient groups during bypass
and this was most noticeable in the ‘bleomycin-pos-
itive’ patients whose plasma transferrin iron loading
signi¢cantly increased (Tables 2^5). Each individual
patient showing bleomycin-detectable iron, at a given
time point, had fully iron-loaded (100% saturated)
Table 2
Changes in plasma iron values of neonates (up to 1 month) undergoing cardiopulmonary bypass (CPB)
N = 12 Total non-haem iron
(nmol/mg protein)
Total iron binding capacity
(nmol/mg protein)
Transferrin
(g/l)
% Saturation
of transferrin
Bleomycin-detectable iron
(BLM-Fe) (Wmol/l)
Pre CPB
BLM-Fe 3ve 0.424 þ 0.04 0.822 þ 0.07 1.73 þ 0.16 53.3 þ 4.9 0
BLM-Fe +ve 0.465 þ 0.20 0.593 þ 0.08 1.36 þ 0.29 60.9 þ 23.6 4.99 (1 sample)
CPB on
BLM-Fe 3ve 0.359 þ 0.03 0.573 þ 0.06 0.80 þ 0.07 63.0 þ 4.8 0
BLM-Fe +ve 0.392 þ 0.11 0.618 þ 0.09 0.66 þ 0.04 69.6 þ 23.3 0.66 (1 sample)
Cross clamp o¡
BLM-Fe 3ve 0.411 þ 0.04 0.640 þ 0.07 0.99 þ 0.14 66.5 þ 5.4 0
BLM-Fe +ve 0.515 þ 0.11 0.527 þ 0.06 0.64 þ 0.05 92.6 þ 7.4 0.69 (1 sample)
CPB o¡
BLM-Fe 3ve 0.375 þ 0.04 0.650 þ 0.06 1.07 þ 0.14 58.4 þ 5.1 0
BLM-Fe +ve 0.590 þ 0.08* 0.510 þ 0.05 0.75 þ 0.09 98.5 þ 1.5* 0.47 þ 0.17(3 samples)
2 h post CPB
BLM-Fe 3ve 0.520 þ 0.05 0.748 þ 0.08 1.36 þ 0.12 69.6 þ 4.3 0
BLM-Fe +ve 0.597 þ 0.27 0.639 þ 0.12 1.32 þ 0.23 81.7 þ 18.4 0.73 (1 sample)
Plasma samples which contained non-transferrin bound LMrFe which was detectable using the bleomycin assay (BLM-Fe +ve) at any
time point during CPB were compared with those which did not show the presence of non-transferrin bound iron (BLM-Fe 3ve).
One neonate showed the presence of BLM-Fe before bypass (4.99 Wmol/l), and such iron was present in the plasma of this patient at
all time points during bypass. At the time point ‘CPB o¡’ two other neonates became iron overloaded. These three neonates have
been grouped together and compared with the nine neonates who did not show iron overload at any time during CPB. Results are
shown as mean þ S.E.M. *P6 0.05.
Table 3
Changes in plasma iron values of infants (1 month to 1 year) undergoing cardiopulmonary bypass (CPB)
N = 26 Total non-haem iron
(nmol/mg protein)
Total iron binding capacity
(nmol/mg protein)
Transferrin
(g/l)
% Saturation
of transferrin
Bleomycin-detectable iron
(BLM-Fe) (Wmol/l)
Pre CPB
BLM-Fe 3ve 0.393 þ 0.04 1.12 þ 0.06 2.15 þ 0.11 35.7 þ 3.0 0
BLM-Fe +ve 0.515 þ 0.05* 1.29 þ 0.13 2.09 þ 0.30 40.7 þ 2.8 0
CPB on
BLM-Fe 3ve 0.531 þ 0.05 0.962 þ 0.04 1.06 þ 0.07 51.3 þ 3.8 0
BLM-Fe +ve 0.559 þ 0.09 0.938 þ 0.25 1.14 þ 0.30 67.8 þ 13.0 0.348 þ 0.33 (2 samples)
Cross clamp o¡
BLM-Fe 3ve 0.428 þ 0.03 0.878 þ 0.04 1.23 þ 0.1 49.7 þ 3.3 0
BLM-Fe +ve 0.674 þ 0.23 1.066 þ 0.40 1.12 þ 0.5 65.3 þ 34.8 0.24 (1 sample)
CPB o¡
BLM-Fe 3ve 0.493 þ 0.04 0.966 þ 0.05 1.41 þ 0.13 51.9 þ 3.7 0
BLM-Fe +ve 0.887 þ 0.12* 0.885 þ 0.16 0.92 þ 0.19 97.6 þ 2.1* 0.623 þ 0.29 (5 samples)
2 h post CPB
BLM-Fe 3ve 0.571 þ 0.05 0.946 þ 0.08 1.83 þ 0.11 61.4 þ 4.7 0
BLM-Fe +ve 1.040 þ 0.06* 0.885 þ 0.08 1.51 þ 0.15 100 þ 0.03* 2.77 þ 2.07 (3 samples)
No infant showed the presence of BLM-Fe before bypass. However, ¢ve infants went into iron overload at various time points during
CPB. Statistical comparisons are made as described in the footnote to Table 2.
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transferrin, although this is not always obvious from
the mean values shown. All bypass patients who did
not show the presence of bleomycin-detectable iron
nevertheless increased the iron saturation of their
transferrin to twice the normal level (60%) during
the bypass procedure (Tables 2^5). 18.5% of infants
showed iron overload during cardiopulmonary by-
pass whereas 14.3% of children 1^5 years, and no
children above the age of 5 showed iron overload
(Tables 3^5).
4. Discussion
Extracorporeal circulation of blood during cardio-
pulmonary bypass surgery exposes cells to non-phys-
iological surfaces and shear stresses, which activate
several regulatory enzyme cascades, activate neutro-
phils to release superoxide and hydrogen peroxide,
and lyse red blood cells to release their contents in-
cluding haemoglobin [14]. Hydrogen peroxide can
react with haemoglobin to form a ferryl iron species
and a protein radical [15], and if su⁄cient H2O2 is
present the iron^protein complex of haemoglobin
fragments to release LMrFe detectable by the bleo-
mycin assay [15]. We speculate that the origin of this
LMrFe seen during cardiopulmonary bypass surgery
is from haemoglobin and not from ferritin, since lev-
els of this protein on the whole do not increase dur-
ing bypass surgery. Additionally changes in iron re-
lease are in parallel with an increase in thiols seen
during cardiopulmonary bypass [13]. The source of
these thiols is thought to be from haemolysis of red
blood cells during surgery, which contain high levels
of the thiol group containing molecule glutathione
(approximately 800 WM per litre of blood). Hydrogen
peroxide is formed by activated phagocytic cells, and
also comes from biochemical reactions initiated dur-
ing the period of ischaemia^reperfusion when the
aortic cross clamp is released. Aberrant ATP catab-
olism during cardiopulmonary bypass ischaemia
causes a signi¢cant increase in plasma hypoxanthine
levels [16]. Hypoxanthine (a substrate for xanthine
oxidase, an enzyme formed from xanthine dehydro-
genase by oxidative or proteolytic modi¢cation) is
converted to uric acid with the formation of super-
oxide radicals and H2O2.
The type of cardioplegia used in adult cardiopul-
monary bypass has been shown to in£uence levels of
both hypoxanthine [16] and LMrFe in the plasma
[13]. In this study, neonates, infants, and children
received either crystalloid or cold blood cardioplegia,
and of those receiving blood cardioplegia 82% were
in iron overload at some point during cardiopulmo-
Table 4
Changes in plasma iron values of children (1^5 years) undergoing cardiopulmonary bypass (CPB)
N = 21 Total non-haem iron
(nmol/mg protein)
Total iron binding
capacity (nmol/mg
protein)
Transferrin
(g/l)
% Saturation
of transferrin
Bleomycin-detectable iron
(BLM-Fe) (Wmol/l)
Pre CPB
BLM-Fe 3ve 0.363 þ 0.02 1.050 þ 0.07 2.31 þ 0.12 36.3 þ 2.3 0
BLM-Fe +ve 0.394 þ 0.07 0.983 þ 0.11 2.12 þ 0.42 41.9 þ 11.0 0
CPB on
BLM-Fe 3ve 0.408 þ 0.02 0.933 þ 0.09 1.10 þ 0.09 49.3 þ 4.0 0
BLM-Fe +ve 0.594 þ 0.09* 0.833 þ 0.02 0.96 þ 0.23 71.7 þ 11.4 0
Cross clamp o¡
BLM-Fe 3ve 0.421 þ 0.02 0.871 þ 0.09 1.13 þ 0.1 54.7 þ 5.2 0
BLM-Fe +ve 0.609 þ 0.09* 0.732 þ 0.14 0.97 þ 0.3 79.7 þ 17.8 0.088 þ 0.07 (2 samples)
CPB o¡
BLM-Fe 3ve 0.443 þ 0.02 0.855 þ 0.06 1.32 þ 0.08 53.9 þ 3.3 0
BLM-Fe +ve 0.494 þ 0.13 0.759 þ 0.13 1.37 þ 0.30 61.0 þ 19.6 0.241 (1 sample)
2 h post CPB
BLM-Fe 3ve 0.520 þ 0.04 0.766 þ 0.03 1.63 þ 0.03 68.1 þ 4.4 0
BLM-Fe +ve 0.605 þ 0.13 0.834 þ 0.05 1.65 þ 0.14 72.8 þ 14.8 0.146 (1 sample)
None of the children (1^5 years) showed the presence of BLM-Fe before bypass. However, three of the children went into iron over-
load during the bypass procedure. See Table 2 for method of statistical analyses.
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nary bypass. This observation suggests that blood
cardioplegia may put paediatric patients at greater
risk of oxidative stress. Overall, neonates showed a
higher incidence of plasma iron overload than that
seen in adults, whereas infants showed a pattern sim-
ilar to that seen in adults randomised to receive all
three cardioplegia regimens [13]. It could be argued
that the higher incidence of iron overload in the neo-
nate group could be attributed to the longer cross
clamp and bypass times (see Table 1). However, we
have previously shown di¡erential iron release in an
adult cardiopulmonary bypass population receiving
di¡erent cardioplegia regimes who had comparable
cross clamp and bypass times to each other [13].
Children in the age group 1^5 years showed a lower
incidence of iron overload than adults, and children
over 5 years showed no cases of iron overload, prob-
ably re£ecting their higher plasma transferrin levels.
Adult patients undergoing cardiopulmonary bypass
have previously been shown to have low plasma
transferrin levels, and to have decreased antioxidant
protection against iron toxicity [17].
Levels of non-haem iron increased in the plasma
of neonates, infants and children (who did not show
bleomycin-detectable iron) during the bypass proce-
dure, to cause increased loading of the transferrin
with iron by up to 60%.
In adult cardiopulmonary bypass patients it is well
established that mild lung injury is a common com-
plication of surgery, and previously [18] we have
demonstrated that during cardiopulmonary bypass,
lung permeability correlates with the iron loading
of transferrin. LMrFe is a potent catalyst for a vari-
ety of oxidative reactions, often involving free radi-
cals (reviewed in [19]), as well as a virulence factor
for microbial growth [20]. It is, therefore, important
to control or remove LMrFe from the plasma. Data
presented here support the postulate that neonates
are at greater risk from iron overload during cardi-
opulmonary bypass, and suggest that some form of
iron chelation therapy might be considered. For neo-
nates, with a permeable blood^brain barrier, this
may best be given in the form of a recombinant
human transferrin or lactoferrin, whereas for chil-
dren and adults, a low molecular mass iron chelator
such as desferrioxamine may be more suitable.
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Table 5
Changes in plasma iron values of children (5^10 years) undergoing cardiopulmonary bypass (CPB)
N = 6 Total non-haem iron
(nmol/mg protein)
Total iron binding
capacity (nmol/mg
protein)
Transferrin
(g/l)
% Saturation
of transferrin
Bleomycin-detectable iron
(BLM-Fe) (Wmol/l)
Pre CPB
BLM-Fe 3ve 0.398 þ 0.04 0.925 þ 0.06 2.06 þ 0.11 44.8 þ 6.8 0
BLM-Fe +ve 0 0 0 0 0
CPB on
BLM-Fe 3ve 0.501 þ 0.07 0.899 þ 0.11 1.28 þ 0.14 59.2 þ 9.0 0
BLM-Fe +ve 0 0 0 0 0
Cross clamp o¡
BLM-Fe 3ve 0.484 þ 0.09 0.843 þ 0.12 1.29 þ 0.16 63.2 þ 15.2 0
BLM-Fe +ve 0 0 0 0 0
CPB o¡
BLM-Fe 3ve 0.562 þ 0.08 0.966 þ 0.09 1.45 þ 0.12 61.3 þ 9.7 0
BLM-Fe +ve 0 0 0 0 0
2 h post CPB
BLM-Fe 3ve 0.513 þ 0.06 0.886 þ 0.08 1.77 þ 0.07 59.1 þ 6.3 0
BLM-Fe +ve 0 0 0 0 0
None of the children (5^10 years) showed the presence of BLM-Fe before or during the bypass procedure.
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